Registered Nurse-Antenatal

M42 advances Central Asia ambitions as Diaverum enters Kyrgyzstan, marks 10 years in Kazakhstan. 22 Sep 2026 15:06 ABU DHABI (WAM) M42, a global health leader powered by artificial intelligence (AI), technology and genomics, today announced that its world-leading renal care business, Diaverum, is opening its first clinic in Kyrgyzstan, marking an expansion for M42 in the Central Asia region. This expansion comes as Diaverum celebrates its 10-year anniversary in Kazakhstan, the largest country in the region, and follows M42's strategic partnership with Uzbekistan's Ministry of Health to collaborate and explore opportunities for strategic partnerships on the Uzbek Genome Programme. Combined, M42's growing presence in the region reflects its ambition to support healthcare systems by combining specialised care delivery with capabilities in genomics, AI, and digital health. Located in Bishkek, the new Diaverum clinic in Kyrgyzstan creates a platform for future growth and collaboration with the local healthcare system. Nearly half a million adults in Kyrgyzstan are estimated to be living with chronic kidney disease, with recent research indicating a prevalence of 10.8% among the country's adult population, underlining the need for accessible, high-quality renal care. The clinic's official inauguration was hosted by Amantur Ryskulov, General Manager, Diaverum Southeast Asia and Central Asia, and attended by Ziyad Kabli, Chief Operations Officer, M42 Middle East and Asia, together with other members of the regional leadership team at M42; Mohamed Salmeen, Head of Support Services, Consular Affairs and Nationals Services Section at the UAE Embassy in Bishkek; Nurlan Mamyrov, Honorary Consul of Sweden to the Kyrgyz Republic; the management of the Ministry of Health of the Kyrgyz Republic and the National Investment agency under the President of the Kyrgyz Republic, as well as senior representatives from public health authorities and other government bodies. The clinic will begin operations with 15 dialysis stations running three shifts from Monday to Saturday, with the potential to expand capacity to 20 stations over time. It will introduce Diaverum's established AI-enabled, patient-centred Care Delivery Model, combining international clinical standards, strong clinical governance and local expertise to support safe, consistent and high-quality care. While initially focusing on delivering high-quality dialysis services, the Bishkek clinic aims to work with local healthcare stakeholders to support a broader approach to kidney health, including prevention, early intervention, peritoneal dialysis, home care and the coordinated management of related health conditions. Group Chief Executive Officer of M42, Dimitris Moulavasilis, commented on the opening, "At M42, we are building a global health intelligence platform that brings together clinical expertise, technology, data and genomics to address complex health challenges. Our growth in Central Asia demonstrates how our model can support different healthcare priorities from specialised renal care in Kazakhstan and Kyrgyzstan to advancing prevention-first care in Uzbekistan. Through strong local partnerships, we aim to contribute to more connected, sustainable and future-ready healthcare systems across the region that serve people with their healthcare needs." Chief Operating Officer, Middle East & Asia at M42, Ziyad Kabli, said, "Central Asia is an important growth region for M42, and our approach is grounded in long-term collaboration aligned with local healthcare priorities. Kazakhstan demonstrates what can be achieved through sustained commitment, while our entry into Kyrgyzstan expands access to high-quality renal care. Alongside our partnership in Uzbekistan, these developments demonstrate M42's commitment to more integrated, preventive and data-enabled healthcare across the region." The expansion into Kyrgyzstan builds on Diaverum's decade-long contribution in Kazakhstan. Since entering the country with nine clinics, Diaverum has grown into Kazakhstan's largest private dialysis provider, operating a nationwide network of more than 55 clinics, serving thousands of patients and employing over 1,000 healthcare professionals and support staff. As M42 continues to expand globally, its engagement across Kazakhstan, Kyrgyzstan, and Uzbekistan demonstrates its diverse capabilities to support the priorities of different healthcare systems.

M42 to adopt Oracle Health Data Intelligence to advance AI-powered precision healthcare in UAE. WAM 15 Sep 2026, 15:33 GMT+ ABU DHABI, 15th September, 2026 (WAM) - M42, a global health leader powered by AI, technology and genomics, today announced plans to adopt Oracle Health Data Intelligence to help unify clinical, genomic and real-world data across its network, advancing chronic disease management, population health programmes and precision care delivery. The collaboration marks another milestone in M42's ongoing efforts to strengthen the UAE's position as a global hub for healthcare innovation and AI-enabled healthcare transformation. Through the integration of Oracle Health Data Intelligence with Oracle Health Foundation EHR, M42 aims to create a secure, scalable and intelligent healthcare ecosystem that enables clinicians and researchers to generate faster insights, enhance care coordination and improve patient experiences. M42's broader vision is to unlock the full potential of Oracle Health solutions across its network to deliver a more connected clinician experience and seamless patient journeys. By centralising diverse healthcare data sources into a unified environment, the platform will help equip clinicians with actionable insights at the point of care while enabling more informed and personalised healthcare delivery. As healthcare systems increasingly rely on complex and rapidly expanding datasets, the collaboration will further strengthen M42's ability to harness data intelligence to optimise healthcare delivery, support healthier populations and accelerate innovation in AI-driven care models and medical research. Underpinned by comprehensive data, digital and AI governance principles, it will help ensure healthcare data is managed securely and responsibly, enabling trusted innovation while supporting regulatory compliance. The announcement builds on the strategic collaboration launched last year between M42 and Oracle Health to support the creation of unified longitudinal patient records accessible across the UAE healthcare ecosystem. As part of that initiative, the organisations successfully integrated data from the Emirati Genome Programme into the electronic health record system to make pharmacogenomic information available to clinicians to support more personalised, data-driven treatment pathways. Dr. Ali Anees, Chief Operating Officer UAE and Bahrain at M42, said, "M42 has a long-standing strategic relationship with Oracle Health, and the adoption of Oracle Health Data Intelligence represents an important step forward in our mission to redefine the future of healthcare through AI and data." He added, "By bringing together clinical, genomic and real-world data into one secure and intelligent environment, we are enabling faster discovery, more predictive insights, and more personalised care for patients. This initiative strengthens our ability to translate data into meaningful health outcomes while advancing the UAE's vision for AI-powered healthcare innovation." The initiative will also support M42's vision to create a comprehensive longitudinal patient record, equipping clinicians across its network with a more complete understanding of patient health histories to support informed clinical decision-making and seamless care coordination. From a population health perspective, the unified platform will enable advanced analytics and AI-driven exploration across large datasets, helping researchers identify disease patterns, correlations and risk factors more efficiently. Built-in AI capabilities will support earlier detection of emerging health trends and treatment opportunities that may otherwise be difficult to identify through traditional analysis methods. Seema Verma, Executive Vice President and General Manager, Oracle Health and Life Sciences, said, "Oracle Health's collaboration with M42 reflects our shared commitment to harnessing the full value of healthcare data, genomics, and AI to transform patient care and accelerate innovation." She added, "M42 continues to demonstrate global leadership in AI-enabled healthcare innovation, and this collaboration highlights how advanced data platforms can help improve research, care delivery and population health outcomes at scale." M42 plans to initially deploy Oracle Health Data Intelligence within its diabetes programmes, enabling proactive patient engagement and care optimisation to help improve long-term health outcomes for individuals living with chronic conditions.

M42 makes ADIHEX debut, spotlighting environmental intelligence. WAM 04 Sep 2026, 16:06 GMT+ ABU DHABI, 4th September, 2026 (WAM) - M42, a global health leader powered by artificial intelligence (AI), technology and genomics, is participating for the first time at the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX), taking place until 6th September 2026 at ADNEC Centre Abu Dhabi. At ADIHEX, M42 is spotlighting its growing work in environmental intelligence and how advanced science, AI and data can generate insights that support public health, environmental resilience and community wellbeing. At the centre of M42's participation is RASID, an AI-powered platform that measures a city's health by transforming wastewater sample analysis into hyper-localised and predictive city health intelligence. Developed in partnership with the Abu Dhabi Quality and Conformity Council (ADQCC), the platform is designed to help authorities detect emerging public health risks through wastewater analysis across 100 testing sites in Abu Dhabi, predictive analytics and AI-supported insights that inform data-driven decision-making. Eng. Abdulla Hassan Al Muaini, Executive Director - Central Testing Laboratory, said, "Strengthening Abu Dhabi's quality infrastructure means continually evolving how we understand and respond to the factors that shape community wellbeing and quality of life. Through our work with M42 on RASID, we are bringing together complementary expertise in environmental monitoring, science and technology. ADIHEX is an opportunity to demonstrate the value of this collaborative approach and its contribution to a healthier, safer and more resilient Abu Dhabi." Operational since 2022, the RASID Laboratory has analyzed more than 75,000 wastewater samples across the UAE, covering more than 400 chemical and biological analytes. This work has created one of the region's largest wastewater surveillance datasets, offering a clearer view of public health, environmental quality and community trends. Dimitris Moulavasilis, Group Chief Executive Officer, M42, said, "Our environment tells us a great deal about the health and wellbeing of our communities. By interpreting these signals, we can generate actionable intelligence that supports earlier, more informed decision making. At ADIHEX, we are demonstrating how the full power of M42's intelligence infrastructure and capabilities can advance human, animal and environmental health to support the UAE's growth, resilience and prosperity." Unlike traditional environmental monitoring, which typically provides a snapshot at a particular point in time, RASID is designed for continuous, population-level monitoring. Its AI models analyse large wastewater datasets to determine a city's health by creating an AI-generated risk score for all threats, use predictive analytics to forecast risk and support with source identification to help channel resources and response. Visitors can explore M42's environmental intelligence capabilities at Stand A-001 & A-003, located in the Preservation of Environment & Cultural Heritage section at ADIHEX 2026. In addition to RASID, M42 will also be showcasing its other capabilities that are advancing innovation in health for people and the planet, including specialist clinical care, genomics and digital health.